Sotrastaurin is a potent inhibitor of alloreactivity in vitro, while it did not affect Selleckchem Paclitaxel Treg function in patients after kidney transplantation. Various immunosuppressive regimens are used in autoimmune disease and clinical transplantation, balancing between clinical efficacy and safety profiles. In solid organ transplantation, regimens to prevent rejection of the donor organ usually include two to four classes of immunosuppressive drugs, of which calcineurin inhibitors (CNI) are the cornerstone. However, well-known side effects include nephrotoxicity, glucose intolerance, malignancy,

hypertension and neurotoxicity [1]. Therefore, there is a strong clinical need for safer and more selective immunosuppressive agents that specifically target a particular molecule or pathway. Interference in the protein kinase C (PKC) signalling pathway by the novel immunosuppressant

sotrastaurin provides this opportunity. PKC is a family PLX4032 of serine and threonine kinases that phosphorylate a wide variety of target proteins which are activated after T cell receptor and co-stimulation receptor (i.e. CD28) triggering [2]. PKC members are divided into three subclasses due to their structure and type of activation: classical, novel and atypical PKC. The classical isoforms α and β and the novel isoform θ are essential for T and B cell activation [3]. Most isoforms are expressed ubiquitously, whereas PKC θ is found predominantly in haematopoietic (and muscular) cells. After accumulation of PKC ε and PKC η in the immunological synapse [4], PKC θ is translocated to the membrane upon T cell receptor activation and activates the nuclear factor (NF)-κB transcription factor. NF-κB binds to the promoter of interleukin (IL)-2, interferon (IFN)-γ and also of forkhead box protein 3 (FoxP3) genes, prominent players in immune reactivity and regulation

[5-7]. Sotrastaurin is a low molecular mass synthetic compound that potently inhibits the PKC α, β and the θ isoforms resulting in selective NF-κB inactivation, in contrast to calcineurin inhibitors, which inhibit both the NF-κB, p38 and nuclear factor of activated T cells (NFAT) signalling Idoxuridine pathways [8, 9]. Currently, the effect of sotrastaurin on FoxP3+ regulatory T cells and their function is unknown. It has been reported that calcineurin inhibitors affect the expansion and function of controlling regulatory CD4+CD25highFoxP3+ T cells (Tregs) while others, such as rabbit anti-thymocyte globulin (rATG) and mammalian target of rapamycin (mTOR) inhibitors, create a milieu by which these suppressor cells can proliferate [10-12]. Because Tregs require T cell receptor-mediated NF-κB activation and cytokines of the IL-2 family for their development, maintenance and suppressive function, their number and function might be influenced by sotrastaurin. Sotrastaurin has recently been tested in psoriasis [13] and kidney transplantation [14, 15]. Oncology trials in melanoma and lymphoma patients (ClinicalTrials.